An interventional study of Pneumonia Panel by FilmArray in Infectious Disease of Lung, Molecular Diagnosis and Pneumonia, sponsored by Mahidol University. Recruiting at 2 sites in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Mahidol University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the research is to ascertain the influence of a syndromic mutiplex PCR assay (FilmArray) on the management of patients hospitalised in the ICU for severe respiratory disease.
The diagnostic process for pneumonia has become significantly more intricate over the past decade due to the interference of the biological, radiological, and clinical criteria of patients hospitalised in the intensive care unit with the conventional criteria for the diagnosis of severe respiratory diseases. Additionally, patients who are hospitalised in the ICU are at a heightened risk of contracting other associated infections. Consequently, patients are frequently administered antibiotics, whether or not they are effective, as it is challenging to promptly determine the aetiology of their symptoms using conventional methods.
To enhance the diagnostic and therapeutic aspects of their treatment, we implemented a novel syndromic molecular test in our laboratories. This test is designed to expedite and enhance the management of pneumonia and the stewardship of antibiotics. This research will include 80 to 100 adult patients hospitalized in ICU between Feb 2025 and Feb 2027. It will take place within the Siriraj Hospital, Bangkok, Thailand.
Not provided
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
This study's planned enrollment of 64 is below the median of 128 across 978 interventional studies indexed under Pneumonia.
Browse Pneumonia studies →Mahidol University is the lead sponsor of 750 studies on the registry; 123 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria: Patients with following conditions;
Pneumonia panel measurement and changing of antimicrobials according to the result of pneumonia panel
Diagnostic Test: Pneumonia Panel by FilmArray
Standard practice
The Pneumonia Panel comprehensively identifies 33 potential pathogen targets from sputum-like (including endotracheal aspirate) and bronchoalveolar lavage (BAL)-like (including mini-BAL) samples. For 15 of the bacteria, the Pneumonia Panel provides semi-quantitative results, which may help determine whether an organism is a colonizer or a pathogen.
Therapeutic decision [Time Frame: 24 hours following the FilmArray results]
Antibiotic prescription modification following the FilmArray results as: No prescription No change in antibiotic utilization Antibiotic initiation Antibiotic escalation Antibiotic de-escalation Antibiotic discontinuation
Time frame: 24 hours following the FilmArray results
Not enrolling at this site.
Plan to share: No
Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.
Of 260 non-industry interventional studies with no phase under Pneumonia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 24 months is close to that.
Counting every sponsor, half of 267 studies reached it within 22 months; a quarter within 11 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.